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Abstract
The development of B-cell lymphomas has been seldom described in HTLV-1 carriers. We present
the case of an elderly Peruvian HTLV-1 carrier who was diagnosed with EBV-positive diffuse large
B-cell lymphoma. Despite an initial good response to therapy, patient died during treatment due to
fatal Pneumocystis jirovecci pneumonia. EBV infection is characterized by B-cell lymphotropism and
selective immunodeficiency. HTLV-1, on the other hand, induces T-cell dysfunction and B-cell
proliferation. Finally, immunosenescence is characterized by T-cell dysregulation, decreased
apoptosis and cytokine upregulation. In this elderly patient, the combination of EBV and HTLV-1
coinfection and immunosenescence may have played a role in the development of this aggressive
diffuse large B-cell lymphoma. Furthermore, the immunodeficiency caused by the viral infections
and chemotherapy may have played a role in developing life-threatening infectious complications.
Findings
The Epstein Barr virus (EBV) was the first described onco-
virus, which has been associated with the development of
a variety of lymphoproliferative disorders, such as Burkitt
[1], primary CNS [2], NK/T-cell [3], plasmablastic [4] and
Hodgkin lymphoma [5]. EBV infection occurs early in
childhood, and approximately 90 to 95% of adults world-
wide are EBV-seropositive. EBV expression has also been
reported in patients with diffuse large B-cell lymphoma
(DLBCL) [6]. DLBCL is the most common variant of non-
Hodgkin lymphoma in the United States (US) and
accounts for approximately 25–30% of the cases [7]. In
Peru, DLBCL accounts for up to 45% of all lymphomas
and, akin to Asian countries, there is high incidence of T-
cell lymphomas and low incidence of follicular lympho-
mas [8]. On the other hand, the human T-lymphotropic
virus type 1 (HTLV-1) is a retrovirus and is the pathogenic
agent of adult T-cell lymphoma/leukemia (ATLL) and
other diseases [9]. HTLV-1 is endemic in Japan, the Mela-
nesian Islands, the Caribbean, South America, the Middle
East and parts of Africa. The prevalence of HTLV-1 in
Europe and the US is lower than 1%. In Peru, it is esti-
mated that up to 3% of the healthy adult population carry
HTLV-1 [10]. The interaction of these two oncoviruses,
EBV and HTLV-1, has seldom been reported in the medi-
cal literature.
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ical history of hypertension, who presented with a seven-
week history of bilateral cervical node enlargement. The
patient denied weight loss, drenching night sweats or
fever. Physical examination showed an elderly individual
with good performance status (ECOG 1) and non-tender
bilateral cervical lymphadenopathy. No hepatosplenome-
galy was found. CT scans of the neck, chest, abdomen and
pelvis did not reveal other sites of disease. Complete
blood count revealed 6,900 leucocytes per mm3, with
52% neutrophils and 28% lymphocytes; the white blood
cell morphology was unremarkable. Hemoglobin was
13.6 g/dl and platelets 245,000 per mm3. Serum lactate
dehydrogenase (LDH) levels were within normal limits.
Renal and hepatic function tests and immunoglobulin A,
G, M and E quantification were within normal ranges. The
patient was seropositive to HTLV-1 using Western Blot
testing and was seronegative for the Human Immunodefi-
ciency Virus (HIV). Hepatitis B and C and Cytomegalovi-
rus viral capside antigen (CMV VCA) IgM antibodies were
not detected. EBV nuclear antigen IgG was positive, this
pattern is characteristic of past EBV infection. An exci-
sional biopsy from a left cervical lymph node showed a
diffuse, large-cell B-cell morphology. Bone marrow aspi-
ration and biopsy revealed a normocellular marrow show-
ing trilineage hematopoiesis, without evidence of
lymphoma or other morphological abnormalities.
Automated immunohistochemistry studies were per-
formed on paraffin-embedded tissue sections. The tumor
cells were positive for CD20 (Dako, Carpinteria, CA; dilu-
tion 1:100; Figure 1), PAX5 (Santa Cruz Biotechnology,
Santa Cruz, CA; dilution 1:100) and MUM1 (Santa Cruz
Biotechnology; dilution 1:200; Figure 2) and negative for
CD10 (Novocastra; Newcastle upon Tyne, UK; dilution
1:10), BCL-6 (Dako; dilution 1:10), CD30 (Novocastra;
dilution 1:100) and LMP-1 (Dako; dilution 1:100). Auto-
mated chromogenic in situ hybridization (CISH) for
EBER was performed according to the manufacturer's pro-
tocol (Dako), and showed positive nuclear expression in
tumoral cells (Figure 3).
Before treatment, written consent was obtained from the
patient, who was then defined as stage IIA DLBCL with a
low-risk International Prognostic Index (IPI) score of 1
out of 5 (i.e. age older than 60 years). Treatment was
started with cyclophosphamide, doxorubicin, vincristine
and prednisone (CHOP) every 21 days with 25% dose-
reduction of cyclophosphamide and doxorubicin with
granulocyte-colony stimulating factor (G-CSF) support
given patient's age. Four cycles of dose-reduced CHOP
were administered. The patient achieved a complete
response by radiologic criteria after the fourth cycle of
treatment. Before the fifth cycle, the patient developed an
interstitial pneumonia with increased serum LDH levels.
Pneumocystis jirovecci pneumonia (PJP) was confirmed
by immunofluorescent staining. Serology for Legionella,
Chlamydia and Mycoplasma were negative. The patient
died in the Intensive Care Unit 25 days after onset of PJP,
5 months after his lymphoma diagnosis.
EBV is a herpesvirus with demonstrated B-cell lymphotro-
pism. EBV infection starts by attachment of the virus to
the CD21 antigen; this initial step prepares the B-lym-
phocyte for EBV infection and is characterized by
increased production of IL-6 and mRNA along with blas-
tic transformation and mobilization of calcium. EBV is
Immunohistochemical expression of CD20Figure 1
Immunohistochemical expression of CD20. CD20 is a 
pan-B-cell marker, demonstrating the B-cell lineage of this 
lymphoma (100×)
Immunohistochemical expression of MUM1Figure 2
Immunohistochemical expression of MUM1. MUM1 is 
a plasma cell marker and, in DLBCL, is consistent with a non-
germinal center subtype. DLBCL with a non-germinal center 
profile have been associated with worse survival (100×)Page 2 of 4
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acquires a circle-shaped configuration. EBV nuclear anti-
gens (EBNA-LP, -1, -2 and -3) are the first to be produced
after infection; these products are essential for immortali-
zation of the cell and upregulation of the expression of
other molecules and genes such as the latent membrane
proteins (LMP-1 and -2). EBNAs also upregulate c-myc,
which is a well-known human oncogene associated with
cell proliferation. LMPs increase expression of BCL-2 and
drive the cell into a latent state, which is maintained by
the production of EBV-encoded RNA (EBER-1 and -2). In
this way, EBV-infected B-cells enter the resting phase
avoiding immunosurveillance but, due to their activated
phenotype, more prone to develop secondary oncogenic
changes [11]. In the present case, the serologic studies are
consistent with a prior EBV infection and the immunohis-
tochemical studies showed expression of EBER. The pres-
ence of EBNA-2 was observed in 28% of the cases of age-
related EBV-associated lymphoproliferative disorder
reported by Oyama and colleagues [12], which is indica-
tive of a type III EBV latency, similar to the one observed
in some cases of HIV-associated [13] and post-transplant
lymphoproliferative disorders [14]. Genetic factors could
also play a role in the development of EBV-associated
lymphoma; it has been suggested that a genetically deter-
mined susceptibility, possibly based on certain HLA types,
results in an abnormal response to primary EBV infection
in certain parts of Asia [15]. These variations in HLA phe-
notype may provide a basis for the higher frequency of
EBV-positive tumors among Asians. In addition, a recent
study from Japan has shown that patients with EBV-asso-
ciated NK/T-cell lymphomas, nasal type, have a low fre-
quency of the HLA-A*0201 allele, suggesting the
importance of this allele in cytotoxic T-lymphocyte
responses [16].
HTLV-1 is a deltaretrovirus that infects a wide variety of cells,
such as lymphocytes, monocytes and fibroblasts by virtue of
its receptor, a commonly expressed transporter of glucose
[17]. HTLV-1 induces a higher rate of production of infected
cells rather than replicating itself, unlike HIV. A first step is to
produce viral-associated proteins such as Tax, which is
encoded in the pX region of the viral genome. Tax increases
proliferation of virus-infected cells by accelerating all the
phases of the cell cycle and renders the affected cells tolerant
to a series of genetic and epigenetic changes [18]. The expres-
sion of Tax wears out as cells acquire the ability to proliferate
independently. Due to its prolonged latency period of 40 to
60 years, HTLV-1 infected cells are more susceptible to
acquire malignant phenotypes in a multistep process. Previ-
ous studies have indicated that the frequency of primary
malignant neoplasms in HTLV-1 carriers is higher than in
HTLV-1 seronegative non-Hodgkin lymphoma cases [19].
HTLV-1 infection is strongly associated to the development
of ATLL and several Peruvian studies on clinical characteris-
tics and outcomes of patients with ATLL have been reported
[20]. Although HTLV-1 has not been associated with the
development of B-cell lymphomas, HTLV-1 carriers with B-
cell lymphoma tend to have a worse prognosis [21]. Theoret-
ically, chronic HTLV-1 infection can cause T-cell dysfunction
and B-cell proliferation inducing a particular state of immu-
nosuppression favoring lymphomagenesis.
As people ages, their immune systems do not respond
adequately to external pathogens or new antigens, such as
immunizations or cancer. T-lymphocytes are greatly
affected by this immune dysregulation state called immu-
nosenescence since the number of naïve T-cells decrease
in peripheral blood and lymph nodes [22], the distribu-
tion of T-cell population is altered [23] and the T-cell
receptor repertoire becomes more limited [24]. The pres-
ence of persistent infections, such as EBV or HTLV-1 or
other persistent antigens, such as cancer will also induce a
phenomenon called immune exhaustion [25]. Other
immunological changes associated with age include
decrease in apoptosis [26] and elevation of levels of proin-
flammatory molecules [27]. This could potentially
explain the increased incidence of cancers in the elderly.
Furthermore, the detection of a type III EBV latency pat-
tern speaks of a severe immunosuppression that could be
partially explained by chronic HTLV-1 infection and/or
immunosencescence. This theoretical relationship is cur-
rently unclear but plausible. To date, there are very few
cases reporting the emergence of lymphoma in patients
with coinfection by EBV and HTLV-1 [28-30].
Likely, HTLV-1 infection will cause chronic immunosup-
presion and activate B-cell proliferation, favoring the
development of EBV infection, which in turn will prepare
Immunohistochemical detection of EBV-encoded RNA (EBER)Figure 3
Immunohistochemical detection of EBV-encoded 
RNA (EBER). Nuclear expression is demonstrated through 
automated chromogenic in situ hybridization (75×)Page 3 of 4
(page number not for citation purposes)
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tending a worse prognosis. It seems intuitive that a patient
with a combination of severe immunological impairment
due to EBV and HTLV-1 infections, immunosenescence
and chemotherapy would develop life-threatening oppor-
tunistic infections, although the occurrence of PJP in
HTLV-1 carriers has seldom been reported in the medical
literature [31,32]. Further research is needed to better
understand the interaction between EBV and HTLV-1 in
lymphomagenesis.
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